“This study is the … largest … to quantify the association of medical and recreational cannabis policies with rates of psychosis-related health care claims across US states. … [W]e did not observe a statistically significant association of state cannabis policy level with overall rates of psychosis-related diagnoses or prescribed antipsychotics.”
A widely reported study appearing today in the British journal The Lancet alleges that an estimated 30 to 50 percent of psychosis cases in Europe are due to cannabis exposure, and that exposure to elevated levels of THC increases this risk.
The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.
Marijuana use by adolescents, including self-reported chronic use, is not associated with adverse health effects later in life, according to an assessment of longitudinal data published in the journal Psychology of Addictive Behaviors. Authors concluded, “Overall, data from this sample provide little to no evidence to suggest that patterns of marijuana use from adolescence to young adulthood … were negatively related to the indicators of physical or mental health studied.”
Last week, in what is becoming a semi-annual mainstream media ritual, news outlets around the globe published sensational headlines alleging that consuming cannabis will drives people crazy.
Cananbidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To…
Every Wednesday on NORML SHOW LIVE, Dr. Mitch Earleywine joins us to discuss the latest…